| Patient | Emile Griffith |
|---|---|
| Date of birth | 1959-02-03 |
| Identifiers | MRN HR-BX005-SYN; SSN (made up) 000-05-6418 |
| Document date | 2026-06-16 |
| Author | Celeste Fairbanks-Ochieng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: neuropsychological testing results and the diagnosis. [S]
Emile Griffith returns with his care partner for the results of his neuropsychological testing, done a week ago, and of the work-up. He has had three sessions of cognitive processing therapy; he says it is hard to write about the fight but he feels lighter after each session, and the psychologist gives him one-page summaries that his care partner reads with him between sessions. Nightmares come four or five nights a week instead of most nights. He takes sertraline 25 mg each morning without side effects. He has had no falls and no thoughts of suicide. His care partner says he repeats stories less when he is rested. He asked to hear the results with his care partner present. [S]
| Element | Detail |
|---|---|
| Neuropsychological testing | Mild cognitive impairment of frontal-subcortical type; retrieval better with cues; effort valid |
| PCL-5 | 37, from 41 at intake |
| PHQ-9 | 8; item 9 scored 0 |
| Therapy | Three sessions of cognitive processing therapy |
| Physical therapy | Evaluation booked for next week |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Forgetfulness, better when rested; no headaches, weakness or tremor |
| Psychiatric | Positive | Nightmares four or five nights a week; less guilt; mood better; no thoughts of suicide |
| Gastrointestinal | Negative | No nausea or diarrhea |
| Musculoskeletal | Negative | No falls |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 25 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-05-05 to 2026-06-16 | completed | S |
| Sertraline 50 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-06-16 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-16 | Body height | 170 | cm | S |
| 2026-06-16 | Body weight | 73.6 | kg | S |
| 2026-06-16 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-06-16 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-16 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-16 | Heart rate | 68 | /min | S |
| 2026-06-16 | Respiratory rate | 14 | /min | S |
| 2026-06-16 | Body temperature | 36.6 | Cel | S |
| 2026-06-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-16 | PTSD PCL-5 score [PCL-5] | 37 | {score} | S |
Vital signs recorded on 2026-06-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 128/78 mmHg; pulse 68; weight 73.6 kg |
| Neurological | Unchanged: no rigidity, tremor or slowness; slightly wide-based gait |
| Mental status | Alert and engaged; asks good questions about the results and repeats the main points back correctly; no psychotic symptoms; denies thoughts of suicide |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss and confusion over about a year, worse in recent months, reported by him and his care partner: repeating stories and questions, losing the thread of conversations, mixing up days, two missed appointments, and once getting lost changing trains on a familiar route; cause to be found | resolved | confirmed | R41.3 | S — Synthetic presenting problem anchored to the documented short-term memory problems; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Post-traumatic stress disorder, chronic, after two index events (a title fight decades ago after which his opponent died, and a severe assault thirteen years ago): nightmares, unwanted images, avoidance of fight footage, guilt and self-blame, being on guard in crowds, poor sleep; PCL-5 41 | active | confirmed | F43.12 | S — Synthetic modern diagnosis at intake by clinical interview against DSM-5-TR criteria, anchored to his public words about lifelong nightmares; not a historical diagnosis. |
| Mild cognitive impairment (mild neurocognitive disorder) with slowed processing, executive and memory-retrieval deficits, most likely due to traumatic brain injury from a nineteen-year professional boxing career and a severe assault; meets the NINDS research criteria for traumatic encephalopathy syndrome (a research diagnosis); Alzheimer's disease co-pathology not excluded | active | confirmed | G31.84 | S — Synthetic modern diagnosis at the third visit after MRI and neuropsychological testing; anchored to the documented memory problems and pugilistic dementia, not a retrospective diagnosis of his real illness. |
| Personal history of traumatic brain injury: repetitive head impacts over 112 professional bouts, and a severe head injury in an assault thirteen years ago with months in hospital | active | confirmed | Z87.820 | S — Synthetic coding of the documented career and assault. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 22 at intake; next in about a year |
| Survey | Staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Up to date | Global CDR 0.5 at two weeks; function unchanged |
| Laboratory | Reversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing and vision | Once at diagnosis | Up to date | Completed at intake and two weeks; no reversible cause found beyond PTSD, depressive symptoms and poor sleep, which are being treated |
| Imaging | Structural brain MRI | Once at diagnosis; repeat only with an atypical course or focal change | Up to date | Done at two weeks; no repeat needed |
| Survey | Neuropsychological testing | At diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with change | Completed today | Testing a week ago reviewed today: slowed processing, reduced set-shifting and fluency, retrieval better with cues; mild cognitive impairment of frontal-subcortical type |
| Laboratory | Alzheimer's disease biomarkers (blood, CSF or amyloid PET) | When the result would change diagnosis or management | Not indicated | Explained and declined for now; would not change his care, and seven microbleeds would exclude anti-amyloid antibodies |
| Examination | Medicine review for anticholinergic, sedating and fall-risk drugs (Beers) | Every visit | Completed today | Sertraline only; no cholinesterase inhibitor started (no benefit shown in mild cognitive impairment) |
| Survey | Neuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity) | Every visit | Completed today | No apathy, irritability, paranoia or impulsive behavior |
| Survey | PHQ-9 with suicide-risk review (item 9 and structured questions) | Monthly during acute treatment; every visit during active treatment | Completed today | PHQ-9 8, item 9 scored 0; no thoughts of suicide |
| Survey | PCL-5 | Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeks | Completed today | PCL-5 37 (41 at intake) |
| Medication safety | Sertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults) | Two weeks after starting and after each dose change; sodium at those points | Ordered | Well tolerated at 25 mg; raised to 50 mg today; sodium due in two to four weeks |
| Referral | Trauma-focused psychotherapy (cognitive processing therapy) | Weekly, about twelve sessions | Up to date | Three of twelve sessions done, adapted with one-page summaries |
| Examination | Fall risk (Timed Up and Go, gait and balance), STEADI | At diagnosis, yearly, and after any fall | Up to date | No falls since intake |
| Referral | Physical therapy for balance and strength | Once, after a Timed Up and Go above 12 seconds | Referred | Rebooked evaluation next week, with a reminder call |
| Self-management | Travel, money and home safety | At diagnosis and each follow-up | Completed today | Address card, shared phone location, company on unfamiliar routes and shared oversight of bills agreed |
| Survey | Care partner support and burden (Zarit Burden Interview, narrative) | At diagnosis, then every 6 to 12 months | Completed today | Zarit Burden Interview 14 (little to mild burden); helpline, caregiver class and GUIDE model explained for if dementia develops |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Due | He wants to name a health care agent soon; booked for the annual wellness visit in seven weeks |
| Examination | Vascular risk factors (blood pressure, weight) | Every visit | Completed today | Blood pressure 128/78 mmHg; weight 73.6 kg |
Goal progress:
Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Guiding an Improved Dementia Experience (GUIDE) Model (2024)
Follow-up: Physical therapy evaluation next week. Annual wellness visit in seven weeks. Four-month review with PCL-5, PHQ-9 and sodium. Call the clinic or 988 at any time if thoughts of suicide arise. Next scheduled visit 2026-08-04: subsequent annual wellness visit. [S]